

Press Release of DOASENSE GmbH

A De Mori appointed as exclusive distributors of DOASENSE solutions in Italy

HEIDELBERG – 14 September 2020 – DOASENSE GmbH, an in vitro diagnostics company focused on the development and commercialization of innovative rapid tests, today announced that A De Mori has been appointed as exclusive distributors of DOASENSE solutions in Italy.

We are delighted to announce the appointment of A De Mori as exclusive distributors of DOASENSE solutions. A De Mori has pioneered the implementation of Point Of Care Testing in Italy and is ideally positioned to promote DOASENSE testing in emergency centers.

“The number of patients on DOACs is growing steadily and it becomes increasingly challenging for emergency clinicians to assess patients. With this novel approach to testing DOACs, DOASENSE is welcomed by the emergency clinician community” says Carlo De Mori, CEO A De Mori. “We are truly excited with this new unique solution which is a perfect fit for our portfolio of Point Of Care Testing”.

The agreement is effective immediately.

Information about DOASENSE solutions in Italy is available from info.ademori@ademorigroup.it
www.ademori.it

About the DOASENSE Product Suite:

The CE-marked DOAC Dipstick is a qualitative all-in-one POCT for both direct factor Xa and thrombin inhibitor DOACs. The test is performed using a urine sample from the patient. The DOAC Dipstick provides results within 10 minutes where they are needed most: at the point-of-care. Specially developed accessories complete the first suite of CE-marked products for rapid point-of-care DOAC testing: Objective documentation of results can be achieved with the compact, automated DOASENSE Reader. And the DOASENSE Control Urines are specially designed reference substances to support quality assurance needs. The in vitro diagnostic products are for professional use only.

About DOASENSE:

DOASENSE is a medical technology company with operations in Heidelberg, Germany. DOASENSE's exclusive, patent protected technology changes the way of testing for direct oral anticoagulants, serving an unmet clinical need.

The company is open to distributor inquiries for further broadening the international market presence of its products.

Contact:

DOASENSE GmbH, Waldhofer Str. 102, 69123 Heidelberg, Germany

info@doasense.de

www.doasense.de